Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenue	$ 26,696	$ 22,302	$ 76,725	$ 60,025
Cost of goods sold	6,444	4,829	18,148	13,352
Gross profit	20,252	17,473	58,577	46,673
Operating expenses:
Research and development	3,076	3,628	11,886	12,812
Clinical and regulatory affairs	1,462	1,179	4,727	2,994
Marketing and sales	12,705	12,331	38,923	33,201
General and administrative	4,942	4,184	13,813	11,087
Contract termination and business acquisition expenses	0	1,300	422	1,730
Settlement costs	5,000	0	5,000	0
Total operating expenses	27,185	22,622	74,771	61,824
Loss from operations	(6,933)	(5,149)	(16,194)	(15,151)
Other income (expense):
Interest income	34	3	24	19
Interest expense	0	(19)	(3)	(28)
Gain on sale of equipment	0	0	0	141
Other income (expense), net	(101)	(38)	(86)	(45)
Change in fair value of contingent consideration related to acquisition	990	(1,400)	(12,700)	(10,000)
Total other expense	923	(1,454)	(12,765)	(9,913)
Net loss before income tax expense	(6,010)	(6,603)	(28,959)	(25,064)
Income tax benefit (expense)	153	0	(297)	0
Net loss	(5,857)	(6,603)	(29,256)	(25,064)
Basic and diluted net loss per share	$ (0.10)	$ (0.12)	$ (0.49)	$ (0.44)
Shares used in computing basic and diluted net loss per share	61,327	56,961	59,224	56,365
Comprehensive loss:
Foreign currency translation adjustment	(139)	0	(32)	0
Comprehensive loss	$ (5,996)	$ (6,603)	$ (29,288)	$ (25,064)